12个月或更长时间对第一个先进疗法的临床反应与长期住院风险的显著降低有关:英国炎症性肠病 (IBD) 患者的全国性分析 生物资源
Kaung Yan1, Sudheer Kumar Vuyyuru2, Adam Taylor1
1Digital Research Service, University of Nottingham, Nottingham, United Kingdom.
Inflammatory bowel diseases
|December 2, 2025
概括
对初始先进疗法的持续反应显著降低了炎症性肠病 (IBD) 患者的长期住院风险. 这凸显了为克罗恩氏病和性结肠炎选择最佳一线治疗的重要性.
科学领域:
- 胃肠病学 胃肠病学
- 临床医学 临床医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 对一线先进疗法的持续反应对炎症性肠病 (IBD) 的住院风险的长期影响尚不清楚.
- 用NIHR IBD BioResource数据库对临床结果进行了回顾性分析.
研究的目的:
- 研究第一种先进疗法的持续反应与IBD患者住院治疗的长期风险之间的关联.
- 评估是否实现早期治疗反应会影响长期疾病管理和结果.
主要方法:
- 包括患有克朗氏病 (CD) 或性结肠炎 (UC) 的成年患者 (≥18岁),接受至少一种先进疗法.
- 治疗反应被定义为持续≥12个月的临床反应或缓解.
- 评估了长期住院的风险,包括IBD相关的手术或需要静脉输入皮质类固醇的疾病恶化.
主要成果:
- 分析了15531名患者 (10,024名CD,5507名UC).
- 82%的CD患者和75.2%的UC患者在第一次先进治疗中获得了持续的反应.
- 持续反应与CD (OR,0.826) 和UC (OR,0.975) 的长期住院风险较低显著相关.
结论:
- 对初始先进疗法的持续反应与IBD住院的长期风险降低有关.
- 优化第一线先进治疗的选择可能会改善长期结果,并减少IBD患者的住院治疗.
相关概念视频
Chronic Bowel Disorders: Introduction
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...


